(129) have also evaluated the synergistic efficacy of MEK plus a histone deacetylase inhibitor, demonstrating that this combination has activity in KRAS-mutant lung cancer cells and might be consider for a promising novel therapeutic approach for patients with NSCLC harbouring KRAS mutations. Here, MAP2K7 is linked to non-small cell lung carcinoma.